 Connection
Mark Boguniewicz to Administration, Topical
This is a "connection" page, showing publications Mark Boguniewicz has written about Administration, Topical.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.641 |
|
|
|
-
Boguniewicz M, Leung DY. The ABC's of managing patients with severe atopic dermatitis. J Allergy Clin Immunol. 2013 Aug; 132(2):511-2.e5.
Score: 0.106
-
Ong PY, Boguniewicz M. Atopic dermatitis. Prim Care. 2008 Mar; 35(1):105-17, vii.
Score: 0.073
-
Boguniewicz M, Abramovits W, Paller A, Whitaker-Worth DL, Prendergast M, Cheng JW, Wang P, Tong KB. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol. 2007 Apr; 6(4):416-23.
Score: 0.068
-
Boguniewicz M, Leung DY. 10. Atopic dermatitis. J Allergy Clin Immunol. 2006 Feb; 117(2 Suppl Mini-Primer):S475-80.
Score: 0.063
-
Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am. 2004 Nov; 24(4):631-44, vi-vii.
Score: 0.058
-
Boguniewicz M. Update on atopic dermatitis: insights into pathogenesis and new treatment paradigms. Allergy Asthma Proc. 2004 Sep-Oct; 25(5):279-82.
Score: 0.057
-
Leung DY, Boguniewicz M. Advances in allergic skin diseases. J Allergy Clin Immunol. 2003 Mar; 111(3 Suppl):S805-12.
Score: 0.052
-
Paller AS, Siegfried EC, Tha?i D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11?years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020 Nov; 83(5):1282-1293.
Score: 0.043
-
Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998 Oct; 102(4 Pt 1):637-44.
Score: 0.038
-
Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics. 2005 Sep; 116(3):e334-42.
Score: 0.015
-
Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, Boguniewicz M, Leung DY. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005 Jun; 115(6):1249-53.
Score: 0.015
-
Abramovits W, Boguniewicz M, Paller AS, Whitaker-Worth DL, Prendergast MM, Tokar M, Tong KB. The economics of topical immunomodulators for the treatment of atopic dermatitis. Pharmacoeconomics. 2005; 23(6):543-66.
Score: 0.015
-
Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K. 1% pimecrolimus cream for atopic dermatitis. Arch Dermatol. 2003 Oct; 139(10):1369-70; author reply 1370-1.
Score: 0.013
-
Ellis CN, Drake LA, Prendergast MM, Abramovits W, Boguniewicz M, Daniel CR, Lebwohl M, Paller AS, Stevens SR, Whitaker-Worth DL, Tong KB. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2003 Apr; 48(4):553-63.
Score: 0.013
-
Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002 Apr; 46(4):495-504.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|